Calyx

Calyx CTMS Select Delivers Robust Functionality for Small/Mid-sized Biopharma and CROs

Retrieved on: 
Monday, November 20, 2023
Clinical trial management system, Organization, CTMS, Clinical trial, Clinical data management, EDC, ChromeOS, Online shopping, Calyx

NOTTINGHAM, England and BILLERICA, Mass., Nov. 20, 2023 /PRNewswire/ -- Calyx, the eClinical and eRegulatory solutions and services provider relied on for solving complex data challenges in clinical research announces an offering for small and mid-sized (SMID) biopharmaceutical companies and CROs that delivers the reliability and global operational support of a proven Clinical Trial Management System (CTMS) with faster implementation times and at lower costs.

Key Points: 
  • CTMS Select is tailored to meet the needs, timelines and budgets of SMID organizations who don't need CTMS customization
    Calyx CTMS Select is a scalable, pre-configured, and validated solution with the rich features required for effective clinical trial management oversight and monitoring.
  • Based on Calyx's 25+ years of expertise supporting diverse trials, it is perfectly tailored to meet the needs, timelines, and budgets of SMID organizations that don't require CTMS customization.
  • Calyx CTMS Select can be implemented in as little as 6-8 weeks and includes out-of-the-box eTMF and EDC integrations and sophisticated features – such as comprehensive site payments – that are rarely included in solutions for smaller organizations.
  • Click here for more information on Calyx CTMS Select.

Calyx CTMS Select Delivers Robust Functionality for Small/Mid-sized Biopharma and CROs

Retrieved on: 
Monday, November 20, 2023
Clinical trial management system, Clinical data management, Clinical trial, ChromeOS, Organization, CTMS, EDC, Online shopping, Calyx

NOTTINGHAM, England and BILLERICA, Mass., Nov. 20, 2023 /PRNewswire/ -- Calyx, the eClinical and eRegulatory solutions and services provider relied on for solving complex data challenges in clinical research announces an offering for small and mid-sized (SMID) biopharmaceutical companies and CROs that delivers the reliability and global operational support of a proven Clinical Trial Management System (CTMS) with faster implementation times and at lower costs.

Key Points: 
  • Calyx CTMS Select is a scalable, pre-configured, and validated solution with the rich features required for effective clinical trial management oversight and monitoring.
  • Based on Calyx's 25+ years of expertise supporting diverse trials, it is perfectly tailored to meet the needs, timelines, and budgets of SMID organizations that don't require CTMS customization.
  • Calyx CTMS Select can be implemented in as little as 6-8 weeks and includes out-of-the-box eTMF and EDC integrations and sophisticated features – such as comprehensive site payments – that are rarely included in solutions for smaller organizations.
  • Click here for more information on Calyx CTMS Select.

National MI Integrates with Calyx Point LOS

Retrieved on: 
Thursday, September 7, 2023
Partnership, API, Calyx, Point, Rate, Real estate

EMERYVILLE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- National Mortgage Insurance Corporation (National MI) , a subsidiary of NMI Holdings, Inc. (NASDAQ: NMIH), is now integrated with Calyx Software’s Point ® loan origination system (LOS).

Key Points: 
  • EMERYVILLE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- National Mortgage Insurance Corporation (National MI) , a subsidiary of NMI Holdings, Inc. (NASDAQ: NMIH), is now integrated with Calyx Software’s Point ® loan origination system (LOS).
  • The integration enables lenders and brokers to order National MI’s real-time, risk-based mortgage insurance through its Rate GPS® tool instantly without having to leave the Point platform.
  • As one of the mortgage industry’s leading LOS for mortgage lenders, Point covers the complete origination process from initial application to closing.
  • “We are pleased to further our partnership with Calyx by integrating with their Point LOS,” said Norm Fitzgerald, chief sales officer with National MI.

Calyx RIM Successfully Implemented by a Global Market Leading Pharmaceutical Company in FDA's eCTD 4.0 Pilot Program

Retrieved on: 
Tuesday, August 8, 2023
CDER, Clinical data management, Center for Drug Evaluation and Research, Feedback, Center for Biologics Evaluation and Research, RIM, Common Technical Document, Army Network Enterprise Technology Command, FDA, Pharmaceutical industry, Calyx, Research

NOTTINGHAM, England and BILLERICA, Mass., Aug. 8, 2023 /PRNewswire/ -- Calyx, the eClinical and regulatory solutions and services provider relied on for solving complex data challenges in clinical research, today announced a major accomplishment in the evolution of its Regulatory Information Management (RIM) system. Calyx has been successfully used by a global market-leading pharmaceutical company to submit key regulatory information to the FDA during its recently completed electronic common technical document (eCTD) 4.0 implementation pilot program.

Key Points: 
  • Calyx has been successfully used by a global market-leading pharmaceutical company to submit key regulatory information to the FDA during its recently completed electronic common technical document (eCTD) 4.0 implementation pilot program.
  • Calyx clients can rely on Calyx RIM as they adopt eCTD 4.0 as part of their global regulatory processes.
  • "We're proud that the advancements we've made to Calyx RIM enabled this market-leading company to succeed during the pilot program and that all of our clients can rely on Calyx RIM as they adopt eCTD 4.0 as part of their global regulatory processes."
  • Visit calyx.ai/RIM for more information on Calyx RIM and its compliance with evolving global eCTD 4.0 regulations.

Calyx RIM Successfully Implemented by a Global Market Leading Pharmaceutical Company in FDA's eCTD 4.0 Pilot Program

Retrieved on: 
Tuesday, August 8, 2023
CDER, Clinical data management, Center for Drug Evaluation and Research, Feedback, Center for Biologics Evaluation and Research, RIM, Common Technical Document, Army Network Enterprise Technology Command, FDA, Pharmaceutical industry, Calyx, Research

NOTTINGHAM, England and BILLERICA, Mass., Aug. 8, 2023 /PRNewswire/ -- Calyx, the eClinical and regulatory solutions and services provider relied on for solving complex data challenges in clinical research, today announced a major accomplishment in the evolution of its Regulatory Information Management (RIM) system. Calyx has been successfully used by a global market-leading pharmaceutical company to submit key regulatory information to the FDA during its recently completed electronic common technical document (eCTD) 4.0 implementation pilot program.

Key Points: 
  • Calyx has been successfully used by a global market-leading pharmaceutical company to submit key regulatory information to the FDA during its recently completed electronic common technical document (eCTD) 4.0 implementation pilot program.
  • "We worked closely with this leading pharmaceutical company and the FDA during the pilot program to continue advancing Calyx RIM based on ongoing feedback and lessons learned," said Jo English, Vice President and General Manager, Enterprise Technology, Calyx.
  • "We're proud that the advancements we've made to Calyx RIM enabled this market-leading company to succeed during the pilot program and that all of our clients can rely on Calyx RIM as they adopt eCTD 4.0 as part of their global regulatory processes."
  • Visit calyx.ai/RIM for more information on Calyx RIM and its compliance with evolving global eCTD 4.0 regulations.

FirstClose™ Equity's Settlement Services Order Management Module Now Integrated with Calyx Point®

Retrieved on: 
Tuesday, July 25, 2023
Data collection, Risk, Growth, The, Bank, Calyx

It also enables lenders to automate data collection, verification, and settlement services ordering.

Key Points: 
  • It also enables lenders to automate data collection, verification, and settlement services ordering.
  • FirstClose's order management module is currently used by more than 200 lenders nationwide to automate back-office manual processes.
  • "We're proud to be integrated with FirstClose and to be able to help our clients streamline their home equity lending operations."
  • "Having our order management module within Point will give Calyx users a simple and efficient way to capitalize on this growing market opportunity and stand out amongst the crowd by offering a significantly enhanced customer experience."

First-person Factory Automation Title Techtonica Arrives on PC and Xbox

Retrieved on: 
Wednesday, July 19, 2023
Electronic Games, Technology, Apps, Applications, Entertainment, Software, Narrative, NT, Catlateral Damage, Friends, Xbox One, Research, Xbox, Xbox Game Pass, Artifact, Steam, Automation, Video game, Calyx

Get ready to shape the terrain and conquer industrial logistics in first-person factory automation title Techtonica, now available on Steam and Xbox Game Pass on the Xbox app, Xbox Series X | S, and Xbox One.

Key Points: 
  • Get ready to shape the terrain and conquer industrial logistics in first-person factory automation title Techtonica, now available on Steam and Xbox Game Pass on the Xbox app, Xbox Series X | S, and Xbox One.
  • Scannable artifacts and research for powerful technologies and enhanced automation systems await players in the caverns.
  • For more information on Techtonica or to talk with other visitors to Calyx, visit the official site or join the official Discord .
  • Construct Your Factory: Power your mining and production with dynamic and interlinked factory systems.

David Herron Appointed as Calyx CEO

Retrieved on: 
Wednesday, April 19, 2023
Professional Services, Health, Technology, Finance, Software, Biotechnology, LLP, Executive, Herron, ERT, Acquisition, Patient, Partnership, Growth, CapVest Limited, Management, Calyx

GLO Healthcare, an expanding healthcare platform formed by CapVest Partners LLP, announces the appointment of David Herron as Calyx Chief Executive Officer (CEO).

Key Points: 
  • GLO Healthcare, an expanding healthcare platform formed by CapVest Partners LLP, announces the appointment of David Herron as Calyx Chief Executive Officer (CEO).
  • Prior to joining Calyx, Herron served as President and CEO of Bioclinica (now part of Clario).
  • Commenting on the appointment, Renaud Dehareng, Executive Chairman of Calyx said: “We are delighted to welcome David to the Calyx team.
  • Kate Briant, Senior Partner at CapVest, will remain a member of the Calyx Board, and as chair of GLO Healthcare.

Calyx Delivers Imaging Biomarkers to Advance Neuropsychiatric Treatment Development

Retrieved on: 
Tuesday, April 4, 2023
Psychiatry, Depressive anxiety, Partnership, Central nervous system, Drug development, Clinical data management, Schizophrenia, Biomarker, Magnetic resonance, CNS, MRI, Acquisition, MD, Biophysics, Parkinson's disease, Artificial intelligence, Regulation, Pharmaceutical industry, Medical imaging, Calyx

NOTTINGHAM, England and MORRISVILLE, N.C., April 4, 2023 /PRNewswire/ -- Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research, today announced a strategic partnership with Ceretype Neuromedicine, Inc., whose novel functional MRI (fMRI) platform incorporates optimal image acquisition and advanced analytics to de-risk and accelerate the development of psychiatric and neurological therapies.

Key Points: 
  • Calyx partners with top tech providers, offering novel imaging biomarkers to find treatments for unmet CNS medical needs
    The current lack of objective biomarkers presents a real challenge for researchers developing treatments for depression/anxiety, schizophrenia, and other neurological/psychiatric conditions such as Parkinson's Disease.
  • "A key component of Calyx's strategy is partnering with best-in-class technology providers to offer the innovative imaging biomarkers required to find new treatments for unmet medical needs," said Stephen M. Bravo, MD, Chief Medical Officer at Calyx.
  • "We're delighted to combine Ceretype's neuroscience, biophysics, and computing expertise with Calyx's 25 years of experience delivering reliable clinical trial imaging," said Emily Stern, CEO at Ceretype.
  • "Through this partnership, we will achieve our mission of improving psychiatric and neurologic patient outcomes through precision drug development and precision treatment."

Calyx Delivers Imaging Biomarkers to Advance Neuropsychiatric Treatment Development

Retrieved on: 
Tuesday, April 4, 2023
Psychiatry, Depressive anxiety, Partnership, Central nervous system, Drug development, Clinical data management, Schizophrenia, Biomarker, Magnetic resonance, CNS, MRI, Acquisition, MD, Biophysics, Parkinson's disease, Artificial intelligence, Regulation, Pharmaceutical industry, Calyx

NOTTINGHAM, England and MORRISVILLE, N.C., April 4, 2023 /PRNewswire/ -- Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research, today announced a strategic partnership with Ceretype Neuromedicine, Inc., whose novel functional MRI (fMRI) platform incorporates optimal image acquisition and advanced analytics to de-risk and accelerate the development of psychiatric and neurological therapies.

Key Points: 
  • The current lack of objective biomarkers presents a real challenge for researchers developing treatments for depression/anxiety, schizophrenia, and other neurological/psychiatric conditions such as Parkinson's Disease.
  • "A key component of Calyx's strategy is partnering with best-in-class technology providers to offer the innovative imaging biomarkers required to find new treatments for unmet medical needs," said Stephen M. Bravo, MD, Chief Medical Officer at Calyx.
  • "We're delighted to combine Ceretype's neuroscience, biophysics, and computing expertise with Calyx's 25 years of experience delivering reliable clinical trial imaging," said Emily Stern, CEO at Ceretype.
  • "Through this partnership, we will achieve our mission of improving psychiatric and neurologic patient outcomes through precision drug development and precision treatment."